SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, announced the publication of preclinical data demonstrating the potential of CLT030,the Company’s CLL1-targeting antibody-drug conjugate (ADC), as a treatment for acute myeloid leukemia (AML). The article appeared today in Blood Advances, a semimonthly, peer-reviewed, online medical journal published by the American Society of Hematology and can be accessed at http://www.bloodadvances.org/content/2/14/1738
CLT030 targets C-type-like lectin 1 (CLL1, also known as CLEC12A), a cell surface antigen expressed in nearly all AML cell subtypes, including leukemic stem cells, but not on normal hematopoietic stem cells. This expression profile differentiates CLL1 from CD33, a common target for targeted AML therapeutics, as it may allow faster hematopoietic recovery in treated patents compared to a CD33-targeting therapeutic. The preclinical data show CLT030 potently kills leukemic stem and blast cells, and has less severe effects on normal hematopoietic stem and progenitor cells compared to a CD33-targeting ADC.
“AML remains a significant unmet medical need, and an ADC that can target leukemic stem cells precisely while minimally affecting normal hematopoietic stem cells could improve outcomes while avoiding much of the toxicities associated with conventional chemotherapy and other targeted therapeutics,” said Ram Mandalam, President and CEO of Cellerant. “We look forward to advancing CLT030 to the clinic.”
Cellerant’s CLT030 development program is supported in part by a grant from the California Institute for Regenerative Medicine (CIRM), an agency of the State of California whose mission is to accelerate stem cell treatments to patients with unmet medical needs.
About Cellerant Therapeutics
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. The romyelocel-L program has been supported by federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services, under contract HHSO100201000051C. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications. For more information, visit: www.cellerant.com